Open-Label Posterior Juxtascleral Injections of Anecortave Acetate 15mg Dose for Long Term Use in Patients With AMD
Status:
Terminated
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the long-term efficacy and safety of posterior
juxtascleral injections of open label Anecortave Acetate 15mg administered every 6 months.